Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in G6PD Deficient Patients
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
A clinical study to assess the safety and efficacy of alternative regimens of primaquine for
radical cure of vivax malaria in glucose 6-phosphate dehydrogenase (G6PD) deficient. G6PD
deficient patients with P. vivax monoinfection will be treated with either weekly or delayed
one-week course of primaquine, and the currently recommended by national guideline, 12-week
chloroquine regimen to compare treatment safety among groups. All groups will be actively
monitored for hemolysis during treatment and will have six-month follow-up period to assess
treatment efficacy.
Phase:
Phase 2
Details
Lead Sponsor:
Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
Collaborators:
Conselho Nacional de Desenvolvimento Científico e Tecnológico Oswaldo Cruz Foundation